ARCHIVES

Groups Point to NCI Restrictions As Source Of Problems, Discuss Prioritizing Trials

This article is from The Cancer Letter archive.

Vol. 29 No. 28 | July 11, 2003

Download PDF Visit The Full Archive

Related Articles

NCI Trials Listed

June 25, 2010

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

April 25, 2014

Professional Societies: AACR To Establish A Foundation To fund Outreach, Education

April 23, 1999

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

February 7, 2014

Reauthorization Battle Warms Up; Administration, But Not Wyngaarden, May OK Cancer Act Renewal

March 18, 1988

NCI contract Awards; RFPs Available; RFAs, PA Available.

October 14, 1994